Program
F-2
Also written as “MK-4082”, “MK-4082 Formulation 2 (F2)” and “MK-4082 Formulation 4 (F4)”.
Its studies are led by Merck.
Furthest: phase 1, since Jan 29, 20263 company-led studies, 1 open or runningNext primary completion: Dec 15, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 31 open or running | phase 1since Jan 29, 2026 | Jan 29, 2026 | Dec 15, 2026phase 1 · NCT07748351 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 29, 2026First study: phase 1 study in HealthyFirst studyNCT07388667 · 122 enrolled · United States
- Jun 23, 2026Phase 1 study in HealthyNCT07697625 · 28 enrolled · United States
- Jul 31, 2026Phase 1 study in HealthyNCT07748351 · 48 enrolled · United States
Ahead
- Dec 15, 2026Primary completion: phase 1 study in HealthyNCT07748351
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07748351Healthy · United States | 1 | Active, not recruiting | Dec 15, 2026 | 48 |
| NCT07697625Healthy · United States | 1 | Completed | Oct 6, 2026 | 28 |
| NCT07388667Healthy · United States | 1 | Completed | Sep 1, 2026 | 122 |
How it is read
Names in the registry
- “MK-4082”, 2 entries
- “MK-4082 Formulation 2 (F2)”, 1 entry
- “MK-4082 Formulation 4 (F4)”, 1 entry
Codes read as this program: MK4082.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.